Researchers at Mount Sinai School of Medicine have determined people who were vaccinated against the 2009 H1N1 influenza virus may also be protected against the lethal 1918 Spanish influenza virus, which killed more than 50 million people worldwide. The new findings are published in the current issue of Nature Communications.
"While the reconstruction of the formerly extinct Spanish influenza virus was important in helping study other pandemic viruses, it raised some concerns about an accidental lab release or its use as a bioterrorist agent," said Adolfo Garcia-Sastre, PhD, Professor, Microbiology, Mount Sinai School of Medicine, lead investigator on the study. "Our research shows that the 2009 H1N1 influenza vaccine protects against the Spanish influenza virus, an important breakthrough in preventing another devastating pandemic like 1918." Other Mount Sinai School of Medicine groups involved in the study include the laboratories of Dr. Palese and Dr. Basler. The study was also done in collaboration with the group of Dr. Belshe, at St. Louis University, who provided the human vaccination samples.
The researchers administered to three groups of mice either the 2009 H1N1 influenza vaccine, the seasonal influenza vaccine, or no vaccine at all. Twenty-one days later, the mice were exposed to a lethal dose of the 1918 Spanish influenza virus. The mice receiving the H1N1 vaccine were the only ones to survive, while also exhibiting limited morbidity following the vaccination.
Additionally, Dr. Garcia-Sastre's team injected the mice with blood serum taken from humans who had been vaccinated against 2009 H1N1 influenza. Later, the mice were given a potent dose of the 1918 Spanish influenza virus. Researchers found that the antibodies in the blood produced by the 2009 H1N1 vaccine may also protect against the 1918 Spanish influenza virus.
"Considering the millions of people who have already been vaccinated against 2009 H1N1 influenza, cross-protection against the 1918 influenza virus may be widespread. Our research indicates that people who were exposed to the virus may also be protected," said Dr. Garcia-Sastre. "We look forward to conducting further research on the benefits of the 2009 H1N1 influenza vaccine in protecting against the deadly 1918 Spanish influenza virus."
This research was funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of few medical schools embedded in a hospital in the United States. It has more than 3,400 faculty in 32 departments and 15 institutes, and ranks among the top 20 medical schools both in National Institute of Health funding and by U.S. News & World Report. The school received the 2009 Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. In 2009, U.S. News & World Report ranked The Mount Sinai Hospital among the nation's top 20 hospitals based on reputation, patient safety, and other patient-care factors. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 530,000 outpatient visits took place.
For more information, visit www.mountsinai.org.